Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Debt / NOTE 0.625% 4/0
-
Number of holders
-
42
-
Total 13F principal, excl. options
-
324,677,440
-
Principal change
-
-59,692,986
-
Total reported value, excl. options
-
$294,978,957
-
Value change
-
-$55,240,585
-
Number of buys
-
18
-
Number of sells
-
-15
-
Price
-
$0.9082
Significant Holders of SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 as of Q4 2019
46 filings reported holding 868459AD0 - SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 as of Q4 2019.
SUPERNUS PHARMACEUTICALS INC - NOTE 0.625% 4/0 has 42 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $324,677,440 of principal
.
Largest 10 bondholders include Allianz Asset Management GmbH ($50,980,000 of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($49,922,000 of principal), M&G INVESTMENT MANAGEMENT LTD ($31,226,000 of principal), CAMDEN ASSET MANAGEMENT L P /CA ($25,150,000 of principal), NN Investment Partners Holdings N.V. ($18,700,000 of principal), JPMORGAN CHASE & CO ($17,696,000 of principal), Invesco Ltd. ($14,627,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($13,838,000 of principal), CALAMOS ADVISORS LLC ($13,008,000 of principal), and STATE STREET CORP ($11,625,000 of principal).
This table shows the top 42 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.